Healthcare / Health Information ServicesNYSE
$7.91
+0.30 (+3.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $169.6M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
N/A
•EV/EBITDA
1.9x
↓ROE
-14.5%
↓Gross Margin
69.5%
↑Debt/Equity
0.75
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
+49.7%
FCF CAGR
—
FCF margin
5.4%
FCF / Net income
-0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.53B · net income $-200.3M · FCF $137.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $2.53B | $2.53B | $2.57B | $2.60B | $2.41B | $2.03B | $1.09B | — | $417.9M | $233.3M | $123.2M | $77.4M | $43.5M | $19.9M |
| Net Income | $-200.3M | $-200.3M | $-1.00B | $-220.4M | $-13.66B | $-428.8M | $-485.1M | $-98.9M | $-97.1M | $-106.8M | $-74.2M | $-58.0M | $-17.0M | $-6.0M |
| EBITDA | $160.6M | $160.6M | $-587.0M | $151.4M | $-13.37B | $-61.4M | $-436.9M | $-41.5M | $-35.3M | $-56.3M | $-54.4M | $-50.9M | $-12.8M | $-5.1M |
| EPS | -34.20 | -34.20 | -176.10 | -40.20 | -2538.00 | -2.73 | -5.36 | -1.38 | — | — | — | — | — | — |
| Gross Margin | 69.5% | 69.5% | 70.8% | 70.8% | 69.1% | — | — | — | 69.2% | 73.6% | 74.0% | 72.8% | 77.2% | 79.0% |
| Operating Margin | -6.5% | -6.5% | -8.1% | -8.1% | -9.4% | -13.1% | -46.3% | — | -17.0% | -32.3% | -50.9% | -72.1% | -34.8% | -29.5% |
| Net Margin | -7.9% | -7.9% | -39.0% | -8.5% | -567.5% | -21.1% | -44.3% | — | -23.2% | -45.8% | -60.3% | -75.0% | -39.1% | -30.2% |
| Balance Sheet | ||||||||||||||
| Debt/Equity | 0.75 | 0.75 | 1.06 | 0.68 | 0.69 | — | — | — | — | — | 0.18 | 0.14 | -0.37 | — |
| Current Ratio | 2.80 | 2.80 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $137.3M | $137.3M | $169.6M | $193.7M | $16.5M | $185.5M | $-57.5M | $26.4M | $-8.9M | $-37.1M | $-54.0M | $-53.5M | — | — |
| Returns | ||||||||||||||
| ROE | -14.5% | -14.5% | -67.1% | -9.5% | -591.9% | -2.7% | -3.1% | -9.7% | -9.6% | -19.1% | -32.1% | -32.5% | 25.2% | 10.9% |
| Valuation | ||||||||||||||
| EV/EBITDA | 1.90 | 1.90 | — | 3.86 | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.03 | 0.03 | 0.04 | 0.05 | 0.05 | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||
| Revenue Growth | -1.5% | -1.5% | -1.3% | 8.1% | — | 85.8% | — | — | 79.1% | 89.4% | 59.2% | 77.8% | 118.7% | — |
| EPS Growth | 80.6% | 80.6% | -338.1% | 98.4% | — | 49.1% | -288.4% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-176.10 → -34.20
Residual
+14.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.